Detalhe da pesquisa
1.
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
N Engl J Med;
366(3): 207-15, 2012 Jan 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22256804
2.
Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.
Bioorg Med Chem;
21(5): 1284-304, 2013 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23376011
3.
Small molecule inhibitors of BRAF in clinical trials.
Bioorg Med Chem Lett;
22(2): 789-92, 2012 Jan 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22222036
4.
Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds.
Bioorg Med Chem;
18(18): 6934-52, 2010 Sep 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20667740
5.
Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold.
J Med Chem;
51(11): 3261-74, 2008 Jun 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18473434
6.
Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead.
J Med Chem;
49(1): 407-16, 2006 Jan 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16392826
7.
Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.
Cancer Res;
62(6): 1724-9, 2002 Mar 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-11912146
8.
The emerging fields of suicide gene therapy and virotherapy.
Trends Mol Med;
8(4 Suppl): S68-73, 2002.
Artigo
em Inglês
| MEDLINE
| ID: mdl-11927291
9.
Introduction to the background, principles, and state of the art in suicide gene therapy.
Mol Biotechnol;
30(1): 71-88, 2005 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15805578
10.
Gene regulation in cancer gene therapy strategies.
Curr Med Chem;
10(20): 2175-84, 2003 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12871091
11.
Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
J Med Chem;
46(9): 1690-705, 2003 Apr 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12699387
12.
Glufosfamide (Baxter Oncology).
Curr Opin Investig Drugs;
3(10): 1527-32, 2002 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12431031
13.
Technology evaluation: EMD-273063, EMD Lexigen.
Curr Opin Mol Ther;
6(5): 559-66, 2004 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15537058
14.
BRAF as a therapeutic target: a patent review (2006 - 2012).
Expert Opin Ther Pat;
23(2): 155-64, 2013 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23294221
15.
Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes.
Cancer Discov;
3(4): 458-469, 2013 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23303902
16.
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Cancer Cell;
20(6): 715-27, 2011 Dec 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22169110
17.
Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
Curr Opin Mol Ther;
12(3): 350-60, 2010 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20521224
18.
BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.
J Med Chem;
53(5): 1964-78, 2010 Mar 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20148563
19.
Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors.
J Med Chem;
53(15): 5639-55, 2010 Aug 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20597484
20.
Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.
J Med Chem;
53(7): 2741-56, 2010 Apr 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20199087